Further Optimization of the mGlu 1 PAM VU6024578/BI02982816: Discovery and Characterization of VU6033685
ACS Chemical Neuroscience · 2025
DOI: 10.1021/acschemneuro.5c00014 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Chemical Neuroscience, 2025. Verfasst von Carson W Reed und 20 weiteren Autor:innen. Beteiligte Einrichtung: Warren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States. Hauptthemen laut MEDLINE: Receptors, Metabotropic Glutamate, Pyridines, Pyrazoles, Quinolines. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIMH NIH HHS, National Institute of Mental Health.
Abstract (Originalsprache)
High Resolution Image Download MS PowerPoint Slide Herein, we report the further chemical optimization of the metabotropic glutamate receptor subtype 1 (mGlu 1 ) positive allosteric modulator (PAM) VU6024578/BI02982816 and the discovery of VU6033685/BI1752. PAM VU6033685/BI1752 was developed through an iterative process wherein, after the furanyl moiety (a potential toxicophore) was replaced by an N -linked pyrazole, a diversity screen identified a quinoline core, which was further truncated to a pyridine scaffold. PAM VU6033685/BI1752 proved to be a potent and selective mGlu 1 PAM with efficacy in both amphetamine-induced hyperlocomotion (AHL) and novel object recognition (NOR) with a clear pharmacokinetic–pharmacodynamic (PK/PD) relationship. VU6024578/BI02982816 was efficacious and well tolerated in rats but not dogs, whereas VU6033685/BI1752 elicited adverse events (AEs) in both rats and dogs. These AEs, noted in two distinct mGlu 1 PAM chemotypes, cast a shadow on an otherwise promising molecular target to address multiple symptom clusters in schizophrenic patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Warren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.
- Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States.
- Vanderbilt Kennedy Center, Vanderbilt University Medical Center, Nashville, Tennessee 37232, United States.
- Vanderbilt Brain Institute, Vanderbilt University, Nashville, Tennessee 37232, United States.
- Vanderbilt Institute of Chemical Biology, Vanderbilt University, Nashville, Tennessee 37232, United States.
- Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88397 Biberach Germany.
ORCID-Profile: Craig W Lindsley
Förderung
- NIMH NIH HHS
- National Institute of Mental Health
Zitieren
APA
Reed, C. W., Kalbfleisch, J. F., Turkett, J. A., Trombley, T. A., Spearing, P. K., Haymer, D. H., Quitalig, M., Dickerson, J. W., Foster, D. J., Blobaum, A. L., Boutaud, O., Cho, H. P., Niswender, C. M., Rook, J. M., Priepke, H., Sommer, H., Scheuerer, S., Ursu, D., Conn, P. J., …, & Lindsley, C. W. (2025). Further Optimization of the mGlu 1 PAM VU6024578/BI02982816: Discovery and Characterization of VU6033685. ACS Chemical Neuroscience. https://doi.org/10.1021/acschemneuro.5c00014
Vancouver
Reed CW, Kalbfleisch JF, Turkett JA, Trombley TA, Spearing PK, Haymer DH, et al. Further Optimization of the mGlu 1 PAM VU6024578/BI02982816: Discovery and Characterization of VU6033685. ACS Chemical Neuroscience. 2025. doi:10.1021/acschemneuro.5c00014
BibTeX
@article{Reed2025,
author = {Reed, Carson W and Kalbfleisch, Jacob F and Turkett, Jeremy A and Trombley, Trevor A and Spearing, Paul K and Haymer, Daniel H and Quitalig, Marc and Dickerson, Jonathan W and Foster, Daniel J and Blobaum, Annie L and Boutaud, Olivier and Cho, Hyekyung P and Niswender, Colleen M and Rook, Jerri M and Priepke, Henning and Sommer, Heiko and Scheuerer, Stefan and Ursu, Daniel and Conn, P Jeffrey and Melancon, Bruce J and Lindsley, Craig W},
title = {Further Optimization of the mGlu 1 PAM VU6024578/BI02982816: Discovery and Characterization of VU6033685},
journal = {ACS Chemical Neuroscience},
year = {2025},
doi = {10.1021/acschemneuro.5c00014}
}
EUVIMED